title: Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry.
abstract: Oxypurinol is the active metabolite of allopurinol which is used to treat hyperuricaemia associated with gout. Both oxypurinol and allopurinol inhibit xanthine oxidase which forms uric acid from xanthine and hypoxanthine. Plasma oxypurinol concentrations vary substantially between individuals and the source of this variability remains unclear. The aim of this study was to develop an HPLC-tandem mass spectrometry method to measure oxypurinol in urine to facilitate the study of the renal elimination of oxypurinol in patients with gout. Urine samples (50 microL) were prepared by dilution with a solution of acetonitrile/methanol/water (95/2/3, v/v; 2 mL) that contained the internal standard (8-methylxanthine; 1.5 mg/L), followed by centrifugation. An aliquot (2 microL) was injected. Chromatography was performed on an Atlantis HILIC Silica column (3 microm, 100 mm x 2.1mm, Waters) at 30 degrees C, using a mobile phase comprised of acetonitrile/methanol/50 mM ammonium acetate in 0.2% formic acid (95/2/3, v/v). Using a flow rate of 0.35 mL/min, the analysis time was 6.0 min. Mass spectrometric detection was by selected reactant monitoring (oxypurinol: m/z 150.8-->108.0; internal standard: m/z 164.9-->121.8) in negative electrospray ionization mode. Calibration curves were prepared in drug-free urine across the range 10-200 mg/L and fitted using quadratic regression with a weighting factor of 1/x (r(2) > 0.997, n=7). Quality control samples (20, 80, 150 and 300 mg/L) were used to determine intra-day (n=5) and inter-day (n=7) accuracy and imprecision. The inter-day accuracy and imprecision was 96.1-104% and <11.2%, respectively. Urinary oxypurinol samples were stable when subjected to 3 freeze-thaw cycles and when stored at room temperature for up to 6h. Samples collected from 10 patients, not receiving allopurinol therapy, were screened and showed no significant interferences. The method was suitable for the quantification of oxypurinol in the urine of patients (n=34) participating in a clinical trial to optimize therapy of gout with allopurinol.
authors.affiliation: Faculty of Pharmacy, University of Sydney, NSW 2006, Australia.
authors.forename: Sophie L
authors.initials: SL
authors.lastname: Stocker
authors.forename: Michael E
authors.initials: ME
authors.lastname: Franklin
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Anderson
authors.forename: Peter I
authors.initials: PI
authors.lastname: Pillans
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Williams
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: McLachlan
authors.forename: Richard O
authors.initials: RO
authors.lastname: Day
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Taylor
mesh_terms: D000493:Allopurinol / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D006073:Gout / Q000188:drug therapy / Q000652:urine; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy / Q000652:urine; D010117:Oxypurinol / Q000652:urine*; D012044:Regression Analysis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D053719:Tandem Mass Spectrometry / Q000379:methods*; D014970:Xanthines / Q000032:analysis
chemical_list: D014970:Xanthines; C008514:methylxanthine; D000493:Allopurinol; D010117:Oxypurinol